Business Context and Reporting Period
Cocrystal Pharma, Inc. (COCP), a Delaware corporation, filed this Form 8-K on January 29, 2020, to report the entry into a Material Definitive Agreement. The Company is listed on The Nasdaq Capital Market.
Key Financial Metrics and Transaction Details
- Transaction Type: Registered offering of common stock.
- Shares Offered: 3,492,063 shares of common stock.
- Offering Price: $0.63 per share.
- Expected Net Proceeds: Approximately $2.0 million (after deducting placement agency commissions and estimated offering expenses).
- Placement Agent Fee: 7% of gross proceeds paid to A.G.P./Alliance Global Partners.
- Use of Proceeds: General corporate purposes and working capital.
- Expected Closing Date: On or about January 31, 2020.
Note: This filing does not provide historical revenue, profit, cash flow, margin, or debt metrics.
Material Changes and Agreements
The primary material change is the execution of a Placement Agency Agreement with A.G.P./Alliance Global Partners and Securities Purchase Agreements with certain investors. The offering is being conducted pursuant to an effective Form S-3 registration statement (No. 333-220632) declared effective on October 10, 2017.
Outlook, Risks, and Unusual Items
- Lock-Up Agreement: Executive officers, directors, and certain principal stockholders have agreed not to sell or transfer Company securities for 30 days following the closing of the Offering.
- Indemnification: The Company agreed to indemnify the placement agent against losses arising from its activities under the agreement.
- Closing Conditions: The transaction is subject to the satisfaction of customary closing conditions.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received, as the $2.0 million figure is an estimate.
- Review the full text of the Placement Agency Agreement (Exhibit 1.1) and Securities Purchase Agreement (Exhibit 10.1) for specific covenants and termination provisions.
- Confirm the filing of the prospectus supplement expected on January 31, 2020, for updated risk factors.
- Monitor the 30-day lock-up expiration date for potential selling pressure from insiders.